Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events such as transient discolouration, altered taste, allergic reaction, hypersensitivity · People undergoing aerosol-generating procedures (AGPs) in a dental setting
The review found no eligible studies for this question.
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Risk of serious adverse events, including those that may be complications of the common cold Duration of · adults and children without colds
1 finding from 1 review
Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain
Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).
1 finding from 1 review
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. · pityriasis rosea
Azithromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review
Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · pityriasis rosea
Erythromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Adverse events: 2. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA SHRS total · people with psychosis
1 finding from 1 review
Adverse events including maternal pregnancy complications, foetal complications and adverse effects of thyroxine · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine led to lower adverse events including maternal pregnancy complications, foetal… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious cardiovascular adverse events ‐ bradycardia 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
1 finding from 1 review
Total number of participants with any adverse events (long‐term data) Treatment duration: range 10 weeks to 12 weeks · participants with acne
It is very uncertain whether benzoyl peroxide changes total number of participants with any adverse events (long‐term… compared with placebo or no treatment (very low certainty).
1 finding from 1 review